glp 1 receptor agonists in idiopathic intracranial hypertension and Excited to share our study @JAMANeuro GLP-1 RA therapy for A glucagon-like peptide-1 receptor agonist

34,35 Subsequently, GLP-1 undergoes enzymatic degradation facilitated by dipeptidyl peptidase IV (DPP-4), leading to the loss of its biological efficacy

AnholmCKumarathuraiPSamkaniAPedersenLRBostonRCNielsenOWet alEffect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial

Adipose tissue reduction: Loss of intrahepatic and visceral fat with GLP-1RAs therapy is associated with decreased release of proinflammatory cytokines such as TNF-, IL-1, and IL-6 (Mehdi et al

It is important to emphasize that GLP-1 therapies do not directly modify fundamental aging mechanisms

Eli Lilly, which also makes the weight loss drugs Mounjaro and Zepbound, said it plans to complete seven additional phase 3 clinical trials of retatrutide in 2026, compiling data that will be submitted to the U.S

cells primarily secrete somatostatin